@article{10.11648/j.ijbecs.20220803.12,
  author = {Andrew Friday and Khaled Alhamad and Gene Grant Finley and Robin Raquel Rodriguez and Herman Lo and Aaron Weidman and Zachary Otaibi and Ashish Sethi and Suneera Bhatia},
  title = {Driver Mutations in Non-Small Cell Lung Cancer: Utility of Liquid Biopsy},
  journal = {International Journal of Biomedical Engineering and Clinical Science},
  volume = {8},
  number = {3},
  pages = {33-39},
  doi = {10.11648/j.ijbecs.20220803.12},
  url = {https://doi.org/10.11648/j.ijbecs.20220803.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbecs.20220803.12},
  abstract = {Non-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patients, oral targeted drugs directed against the mutated gene yield better outcomes than chemotherapy or immunotherapy. Consequently, assessing the tumor for driver mutations has become standard of care in managing nsNSCLC. However, in 20% of lung cancer patients, the tissue biopsy is either unobtainable or insufficient to assay. In these circumstances, analyzing circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from the blood can reveal the driver mutations. A prospective study was conducted with Biocept, to evaluate the clinical utility of a single gene assay using ctDNA and CTCs in patients with advanced NSCLC. Here, we report the comparison between biomarker expression of the tumor tissue and liquid biopsy of matched samples of 40 unique patients. Methods: Matched liquid biopsy and tumor tissue was analyzed from forty unique patients with stage III and IV NSCLC for EGFR, KRAS, BRAF, ALK, and ROS-1. Tissue was analyzed by Next Generation Sequencing (NGS), whereas peripheral blood samples for liquid biopsy was analyzed using circulating tumor DNA (ctDNA) for EGFR, KRAS, and BRAF mutations, and circulating tumor cells (CTCs) for ALK and ROS-1 mutations. Results: 80% of the patients (32/40) received both tissue biopsy and liquid biopsy analysis. The concordance between EGFR, KRAS, BRAF, ALK and ROS-1 between tumor tissue and liquid biopsy was 86%. Furthermore, liquid biopsy demonstrated a higher rate of conclusive results compared to tissue biopsy and led to a change in treatment for in 4 of the 40 patients. Conclusion: This works suggests that tissue and liquid biopsy can be complementary, and liquid biopsy can inform the course of treatment when a tissue biopsy is not available.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Driver Mutations in Non-Small Cell Lung Cancer: Utility of Liquid Biopsy
AU  - Andrew Friday
AU  - Khaled Alhamad
AU  - Gene Grant Finley
AU  - Robin Raquel Rodriguez
AU  - Herman Lo
AU  - Aaron Weidman
AU  - Zachary Otaibi
AU  - Ashish Sethi
AU  - Suneera Bhatia
Y1  - 2022/09/05
PY  - 2022
N1  - https://doi.org/10.11648/j.ijbecs.20220803.12
DO  - 10.11648/j.ijbecs.20220803.12
T2  - International Journal of Biomedical Engineering and Clinical Science
JF  - International Journal of Biomedical Engineering and Clinical Science
JO  - International Journal of Biomedical Engineering and Clinical Science
SP  - 33
EP  - 39
PB  - Science Publishing Group
SN  - 2472-1301
UR  - https://doi.org/10.11648/j.ijbecs.20220803.12
AB  - Non-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patients, oral targeted drugs directed against the mutated gene yield better outcomes than chemotherapy or immunotherapy. Consequently, assessing the tumor for driver mutations has become standard of care in managing nsNSCLC. However, in 20% of lung cancer patients, the tissue biopsy is either unobtainable or insufficient to assay. In these circumstances, analyzing circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from the blood can reveal the driver mutations. A prospective study was conducted with Biocept, to evaluate the clinical utility of a single gene assay using ctDNA and CTCs in patients with advanced NSCLC. Here, we report the comparison between biomarker expression of the tumor tissue and liquid biopsy of matched samples of 40 unique patients. Methods: Matched liquid biopsy and tumor tissue was analyzed from forty unique patients with stage III and IV NSCLC for EGFR, KRAS, BRAF, ALK, and ROS-1. Tissue was analyzed by Next Generation Sequencing (NGS), whereas peripheral blood samples for liquid biopsy was analyzed using circulating tumor DNA (ctDNA) for EGFR, KRAS, and BRAF mutations, and circulating tumor cells (CTCs) for ALK and ROS-1 mutations. Results: 80% of the patients (32/40) received both tissue biopsy and liquid biopsy analysis. The concordance between EGFR, KRAS, BRAF, ALK and ROS-1 between tumor tissue and liquid biopsy was 86%. Furthermore, liquid biopsy demonstrated a higher rate of conclusive results compared to tissue biopsy and led to a change in treatment for in 4 of the 40 patients. Conclusion: This works suggests that tissue and liquid biopsy can be complementary, and liquid biopsy can inform the course of treatment when a tissue biopsy is not available.
VL  - 8
IS  - 3
ER  - 

Copy | Download